Drug development, immunology research, and clinical innovation by Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. unveils updated Phase 1/2 CRB-701 data at ASCO26
Corbus Pharmaceuticals Holdings, Inc. will present updated Phase 1/2 data for its CRB-701 program at the ASCO26 KOL event on June 1. The event will feature clinical response durability and ...
CRB-701 Phase 1/2 data outlines next steps, Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. has provided new insights into the clinical and commercial development path for CRB-701, its key asset targeting second-line oropharyngeal and cervical ...
Corbus Pharmaceuticals Holdings, Inc. appoints Nishant Saxena as chief business officer and schedules data call on CRB-701
Corbus Pharmaceuticals Holdings, Inc. has appointed Nishant Saxena as its new chief business officer, marking a significant addition to the company’s leadership team. The firm also announced it ...
Corbus Pharmaceuticals Holdings, Inc. schedules corporate overview at RBC and Jefferies healthcare events
Corbus Pharmaceuticals Holdings, Inc. will deliver a corporate overview and engage with investors at two influential healthcare conferences. The company is set to participate in the RBC Capital ...
Corbus Pharmaceuticals Holdings, Inc. posts 2026 first quarter financial results and corporate update
Corbus Pharmaceuticals Holdings, Inc. released its corporate update and financial results for the first quarter ended March 31, 2026. The announcement provides investors and stakeholders with ...
Corbus Pharmaceuticals Holdings to unveil new CRB-701 clinical results at ASCO annual meeting
Corbus Pharmaceuticals Holdings, Inc. will host both an in-person and virtual key opinion leader event during the 2026 ASCO annual meeting to share updated results from the Phase 1/2 clinical ...
Corbus Pharmaceuticals Holdings initiates last patient first visit in CANYON-1 obesity trial with 240 participants
Corbus Pharmaceuticals Holdings, Inc. has announced that the last patient has completed their first visit in the CANYON-1 Phase 1b clinical trial of CRB-913, an investigational treatment for ...
Corbus Pharmaceuticals Holdings, Inc. secures ASCO 2026 slot for new CRB-701 clinical findings
Corbus Pharmaceuticals Holdings, Inc. will present updated clinical data from its Phase 1/2 study of CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancer at the 2026 ASCO ...
Corbus Pharmaceuticals Holdings, Inc. secures U.S. FDA alignment on CRB-701 study for HNSCC and cervical cancer
Corbus Pharmaceuticals Holdings, Inc. announced broad alignment with the U.S. FDA on the registration pathway for its investigational drug CRB-701 in second-line head and neck squamous cell ...
Corbus Pharmaceuticals Holdings, Inc. advances next-gen ADC targeting Nectin-4 in aggressive cancers
Corbus Pharmaceuticals Holdings, Inc. is developing a next-generation antibody drug conjugate, CRB-701, designed to treat certain solid tumors that overexpress the Nectin-4 protein. This protein ...
Corbus Pharmaceuticals Holdings, Inc. to present CRB-913 oral CB1 inverse agonist at BMO Summit
Corbus Pharmaceuticals Holdings, Inc. will participate in a panel at the BMO 2026 Metabolic Health Summit, focusing on its investigational therapy CRB-913. The orally delivered CB1 inverse ...
Q4 and annual financial update released, Corbus Pharmaceuticals Holdings, Inc. outlines
Corbus Pharmaceuticals Holdings, Inc. has released its financial results for the fourth quarter and full year ended December 31, 2025. The company provided a detailed corporate update, offering ...
Corbus Pharmaceuticals Holdings, Inc. advances CRB-701 for Nectin-4 solid tumors in early-stage development
Corbus Pharmaceuticals Holdings, Inc. is developing its investigational therapy CRB-701 for patients with advanced solid tumors that exhibit high Nectin-4 expression, including head and neck ...
